Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy (NASDAQ:LGND)
· seekingalpha.com
Ligand Pharmaceuticals earns a BUY rating as royalty growth, the XOMA deal, and Filspari momentum boost earnings and outlook. Discover more on LGND here.
I am an Investment Research Analyst with a strong interest in fundamental equity research, valuation, and long-term investing, with a primary focus on the U.S. ...